|

Inavolisib Clinical Trials

15 actively recruiting trials across 8 locations

▼ -1 trial since May 2026

Also known as: GDC-0077, GDC-0077, RO7113755, ITOVEBI™, Itovebi, RG6114 +1 more

Pipeline

Phase 1: 1Phase 2: 7Phase 3: 3Phase 1/2: 3

Top Sponsors

  • Hoffmann-La Roche11
  • MedSIR1
  • German Cancer Research Center1
  • GBG Forschungs GmbH1
  • Alliance Foundation Trials, LLC.1

Indications

  • Cancer15
  • Breast Cancer11
  • Metastatic Breast Cancer3
  • Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer1
  • Metastatic Castration-resistant Prostate Cancer1

Other5 trials

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
Phase 2
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Phase 3
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
Phase 2
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
Phase 2

Duarte, California3 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

City of Hope

Phase 1/2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2

Birmingham, Alabama1 trial

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

UAB Comprehensive Cancer Center

Phase 1

Gilbert, Arizona1 trial

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Banner Health MD Anderson AZ

Phase 3

Phoenix, Arizona1 trial

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

The Dignity Health Cancer Institute

Phase 3

Los Angeles, California1 trial

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Los Angeles Cancer Network

Phase 2

Orange, California1 trial

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Community Clinical Trials

Phase 2

San Francisco, California1 trial

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

UCSF

Phase 2

Marshall, Minnesota1 trial

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Avera Cancer Institute - Marshall

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.